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PRM225  
MODELING AND ANALYTICS FRAMEWORK FOR VALUE BASED PRICING  
Dinh T1, Newton M2 
1Archimedes Inc., San Francisco, CA, USA, 2Archimedes Inc, San Francisco, CA, USA  
Pharmaceutical companies and payers increasingly engage in value-based 
pricing agreements, which link payment for a medicine to value achieved. 
However, the traditional approach to drug development has been oriented 
towards efficacy and safety and is unable to address the evidence requirements 
from payers and health technology assessors. To support this emerging 
paradigm change in drug development, Archimedes has developed a systematic 
framework that integrates evidence (randomized clinical trials, electronic 
medical records, claims, laboratory results, disease registries) with analytics and 
modeling (predictive modeling, health-economic simulation, cost-effectiveness 
analysis) to provide a comprehensive assessment of all health and economic 
benefits of new interventions – including potential cost savings elsewhere in the 
treatment pathways, improvements in quality of life of patients and caregivers 
as well as other societal benefits. The framework leverages the strength of  
the Archimedes ARCHES Simulation platform as well as a suite of analytic tools 
and services developed specifically to capture values of interventions. It  
also enables probabilistic sensitivity analysis and uncertainty quantification  
of predicted values. The framework is designed to integrate organically with  
the life-cycle of product development. It will help the pharmaceutical companies 
to establish the value-based evidence-generation process, identify 
subpopulations for which their medications are most valuable, and evaluate 
commercial value of new medications as early as possible in the development 
cycle. In this presentation, we will present the key elements of the framework as 
well as the results of a case study, in which the framework is used to  
support value-based pricing for a novel intervention. We will demonstrate how 
costs and benefits of the intervention vary across different subpopulations, 
suggesting a multi-tiered pricing approach may be the optimal strategy for the 
intervention.  
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A MULTIPLE CRITERIA DECISION ANALYSIS FRAMEWORK FOR VALUE BASED 
ASSESSMENT OF NEW MEDICAL TECHNOLOGIES  
Angelis A, Kanavos P 
London School of Economics and Political Science, London, UK  
The use of cost/QALY has been criticised for a variety of reasons, including the 
fact that the QALY does not capture adequately elements associated with burden 
of disease, aspects of product’s innovation level, and wider socioeconomic 
implications. No such ‘holistic’ value based assessment (VBA) method has been 
successfully created yet. Using Multiple Criteria Decision Analysis (MCDA) we 
develop a new methodological framework for assessing the value of new medical 
technologies according to the following procedure: Establish the decision 
context; the decision perspective could potentially adopt a health system’s 
societal point of view. Identify the options; choose the candidate technologies to 
be assessed, e.g. antineoplastic drugs for metastatic colorectal cancer. Identify 
the value objectives/criteria; these should include several technology – disease 
characteristics and could be divided in the areas of: a) burden of illness; b) 
therapeutic improvement; c) quality of life benefits; d) innovation level; and e) 
socioeconomic impact. ‘Scoring’; assess the value associated with the 
consequences of each criterion for each option, e.g. by adopting a direct rating 
approach where the judgment of experts is used to rank the magnitude of value. 
‘Weighting’; assign weights for each of the criteria to reflect their relative 
importance to the decision, e.g. by using a swing weighting method 
implemented in combination with a nominal-group technique where experts 
agree on the relative contribution of each criterion. Produce a value index; 
combine weights and scores for each option to derive an overall index of value, 
e.g. through a weighted average linear additive model. Examine the results and 
conduct a sensitivity analysis; test the impact of changes in scores and weights 
on the overall value. The result would subsequently provide evidence on the 
value of each technology. The methodology could then be applied more 
practically by linking value index scores with reimbursement and/or pricing 
decisions.  
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CONSIDERATIONS IN THE APPPLICATION OF NOVEL STATISTICAL METHODS 
FOR CROSSOVER ADJUSTMENT IN TRIALS OF CANCER TREATMENTS  
Ishak KJ1, Proskorovsky I1, Korytowsky B2, Sandin R3 
1United BioSource Corporation, Dorval, QC, Canada, 2Pfizer Global Pharmaceuticals, New York, 
NY, USA, 3Pfizer Global Pharmaceuticals, Sollentuna, Sweden  
Rank Preserving Structural Failure Time (RPSFT) and Inverse Probability of 
Censoring Weighted (IPCW) models are increasingly applied to adjust for bias in 
treatment effect estimates in trials of cancer drugs where crossover to the new 
treatment is allowed. We review the assumptions and processes underlying 
these methods and their suitability in different situations using a case study. A 
first consideration is the meaning of the cross-over adjusted result, which is an 
estimate of the treatment effect had crossover not occurred – i.e., if patients had 
continued to be treated with standard therapy. This may be plausible when no 
other treatment options are available; otherwise, the crossover-adjusted 
estimate becomes a theoretical upper-bound, and likely not representative of 
real-world effectiveness. The assumptions inherent to each approach must also 
be considered carefully. For instance, RPSFT models shrink the survival time of 
patients who cross-over by a magnitude proportional to the time spent on the 
experimental drug and its associated benefit. Implied here is that patients derive 
the same benefit for every unit of time on the experimental treatment, and that 
this benefit is the same in both the original randomized population and those 
who cross over. The latter are selected, however, based on their expected 
responsiveness to and tolerance of the new treatment. In the IPCW approach 
adjustment is made by analytically matching patients who cross over to patients 
who had a similar prognosis but did not crossover. The prognosis of these groups 
may not overlap sufficiently, however; in fact, full characterization of the 
prognosis of patients may be impossible as it requires time-dependent 
information on factors considered by physicians deciding which patients should 
cross over. This talk aims to promote better understanding of these methods, 
their proper application and interpretation and use of results.  
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NICE'S SELECTIVE APPLICATION OF DIFFERENTIAL DISCOUNTING: 
AMBIGUOUS, INCONSISTENT AND UNJUSTIFIED  
O'Mahony J1, Paulden M2 
1Trinity College Dublin, Dublin, Ireland, 2University of Toronto, Toronto, ON, Canada  
The National Institute for Health and Clinical Excellence (NICE) recently 
recommended differential discounting of costs and health effects in the 
economic appraisal of health care interventions in certain circumstances. The 
recommendation was published in an amendment to NICE’s guide to the 
methods of technology appraisal. The amendment states that differential 
discounting should be applied where “treatment effects are both substantial in 
restoring health and sustained over a very long period (normally at least 30 
years)”. Renewed interest in differential discounting from NICE is welcome; 
however, the recommendation’s selective application of differential discounting 
raises a number of concerns. The stated criteria for applying differential 
discounting are ambiguous. The rationale for the selective application of 
differential discounting has not been articulated by NICE and is questionable. 
The selective application of differential discounting leads to several 
inconsistencies, the most concerning of which is the lower valuation of health 
gains for those with less than 30 years remaining life expectancy, which can be 
interpreted as age discrimination. Furthermore, the discount rates chosen by 
NICE do not appear to be informed by recent advances in the theoretical 
understanding of differential discounting. NICE’s apparent motivation for 
recommending differential discounting was to ensure a favourable cost-
effectiveness ratio for a paediatric oncology drug. While flexibility may be 
appropriate to allow some interventions that exceed conventional cost-
effectiveness thresholds to be adopted, the selective adjustment of appraisal 
methods is problematic and without justification.  
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THE CASE-REFERENT STUDY: ARE DIFFICULTIES IN ITS REPORTING AND 
INTERPRETATION AFFECTING NON-RCT SYSTEMATIC REVIEWS?  
WOULD AN EXTENSION TO STROBE HELP?  
MacGilchrist KS1, Bhopal RS2 
1Abacus International, Bicester, UK, 2Centre for Population Health Sciences University of 
Edinburgh, Edinburgh, UK  
BACKGROUND: The quality of evidence provided by systematic reviews rests on 
clear reporting in original papers. A STROBE checklist aids reporting of case-
control studies, but does not distinguish different case-referent designs. These 
latter include case-base, incidence density and case-exposure designs, as well as 
the (traditionally understood) case-control study. The measure estimated and, if 
an odds ratio, how that may be interpreted, is dependent upon the design. In 
spite of methodology elaborated over four decades, a 2000 review identified 
numerous difficulties with authors’ reporting and interpretation of case-referent 
studies, and a review a decade later indicated that such issues prevailed. 
OBJECTIVE: To provide guidance on reporting of case-referent studies. 
METHODS: Medline search in 2000 for odds ratio, relative risk, rare disease 
assumption and rarity assumption; review of collection of articles from R. 
Bhopal; snowballing. RESULTS: 1) State the reference series sampling scheme. 
Cumulative incidence (traditional or exclusive), incidence density (concurrent) or 
case-base (inclusive), sampling. 2) State whether incident and/or prevalent cases 
enrolled 3) State what your case-referent study is calculating. A true odds ratio 
will only result from a case-controlstudy. Incidence density sampling, where the 
reference series is used to calculate population time, yields an incidence density 
ratio and case-base sampling enables direct calculation of a risk ratio. 4) State 
the formal assumptions made or formulae used 5) Refrain from ‘labelling’ effect 
measures relative risk (especially in the abstract). CONCLUSION: For case-
referent studies to be incorporated into systematic reviews authors should report 
and editors should require greater technical detail. Would an extension of 
STROBE help?  
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PMH1  
COMPARATIVE EFFECTIVENESS OF ANTIPSYCHOTICS AND VALPROATE 
VERSUS ANTIPSYCHOTIC USE ALONE ON THE RISK OF LONG-TERM CLINICAL 
OUTCOMES AND MORTALITY IN THE ELDERLY POPULATIONS WITH 
SCHIZOPHRENIA  
Parente A, Teigland C, Jones B, Mehta S, Chen P, Yang X, Scoggins J 
Inovalon Inc., Bowie, MD, USA  
OBJECTIVES: To evaluate the relative likelihood of cardiac events, pancreatitis, 
pneumonia, and death associated with use of valproate (V) as an adjunct  
“off label” therapy to antipsychotics (AP) in the elderly population with 
schizophrenia. METHODS: This retrospective cohort study utilized a propensity-
score matching technique and a new user design to identify patients in a large 
nationally representative administrative database. The sample included 
Medicaid, Medicare, and Commercial patients aged 65+ with a diagnosis  
